News Releases

Sutro Biopharma to Participate in the 31st Annual Piper Jaffray Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application.. Read More →

Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application.. Read More →

Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments

STRO-002 Initial Safety Data from an Ongoing Phase 1 Trial in Ovarian and Endometrial Cancers presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.. Read More →

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate (ADC), in.. Read More →

Sutro Biopharma to Present at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer – Data is.. Read More →

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – STRO-002 – Abstract

Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety.. Read More →

Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming AACR-NCI-EORTC International.. Read More →

World Anti-Body Drug Conjugate (ADC) 2019 – Process Development and Scale Up for Site-Specific Bioconjugate Conjugation and Purification Poster

World Anti-Body Drug Conjugate (ADC) 2019  Process Development and Scale Up for Site-Specific Bioconjugate Conjugation and Purification Please Click the Link, World ADC 2019 Poster to.. Read More →

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors – Merck KGaA, Darmstadt, Germany Designates Undisclosed Bispecific ADC as.. Read More →

Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, CEO of Sutro Biopharma, will present a.. Read More →

Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments

STRO-001 Initial Safety Data from an Ongoing Phase 1 Trial in Myeloma and Lymphoma presented at the European Hematology Association (“EHA”) Congress, June 15, 2019.. Read More →

Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application.. Read More →

Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair  

Former Biogen Idec executive to bring additional strategic expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., June 24, 2019 — Sutro Biopharma, Inc. (NASDAQ: STRO),.. Read More →

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., June 18, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application.. Read More →

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European.. Read More →

Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress

SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology.. Read More →

Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments

STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European Hematology Association (“EHA”) Congress,  June 15,.. Read More →

Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial.. Read More →

Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers

Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers STRO-002, Sutro’s second clinical program, is designed to deliver.. Read More →

Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 5, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the Cowen.. Read More →

Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry

Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry Veteran Pfizer researcher Andreas Maderna, Ph.D., joins the company SOUTH SAN FRANCISCO, Calif.,.. Read More →

Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th.. Read More →

Sutro Achieves $10 Million Milestone Payment from Celgene

Sutro Achieves $10 Million Milestone Payment from Celgene Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities SOUTH SAN FRANCISCO,.. Read More →

Sutro Biopharma Reports Third Quarter 2018 Financial Results

— STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma — STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers.. Read More →

Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

Initiation of Phase 1 Trial Planned for Early 2019 Company’s Second Cell-Free ADC Addressing Unmet Medical Need in Oncology    SOUTH SAN FRANCISCO, Calif., Nov... Read More →

Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors

Sharp to Bring Additional Financial Expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., Nov. 8, 2018 — Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that.. Read More →

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

A New Generation of Precisely Engineered CD74-Targeting ADC SOUTH SAN FRANCISCO, Oct. 12, 2018– Sutro Biopharma, Inc. (NASDAQ: STRO),has been granted Orphan Drug Designation by.. Read More →

Sutro Biopharma Announces $85.0 Million Initial Public Offering

South San Francisco, California – September 26, 2018.  Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary.. Read More →

Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief

Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief SOUTH SAN FRANCISCO, Sept. 12, 2018 – Sutro Biopharma, Inc., has.. Read More →

Sutro and The Leukemia & Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment

Expand Clinical Research on Patients with Progressive Disease SOUTH SAN FRANCISCO, August 13, 2018– Sutro Biopharma, Inc.,and The Leukemia & Lymphoma Society® , or LLS,.. Read More →

Sutro Biopharma Announces $85.4 Million Series E Round

Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc.,.. Read More →

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

Sutro’s Cell-free Protein Synthesis Technology is Paired With Merck’s Immunology & Cancer Expertise SOUTH SAN FRANCISCO, July 24, 2018 –Sutro Biopharma, Inc., has signed a.. Read More →

Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs

SOUTH SAN FRANCISCO, April 26, 2018 — Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its  potential first-in-class antibody drug.. Read More →

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

– Phase 1 Trial Planned for Late 2018 – Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro.. Read More →

Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies

Results Presented at ASH are a Promising Sign as Company Prepares for STRO-001 Phase 1 Trial SOUTH SAN FRANCISCO, December 12, 2017 — Two studies.. Read More →

Sutro Marks Two Drug Development Milestones

Receives Celgene Payment, Completes Production for Clinical Trials of Internally-Developed ADC SOUTH SAN FRANCISCO, Oct. 11, 2017 — Sutro Biopharma has received a manufacturing milestone.. Read More →

Sutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs

Will Rapidly Advance Promising Drug Candidates to the Clinic   SOUTH SAN FRANCISCO, Aug. 10, 2017 – Sutro Biopharma today announced it is refocusing its.. Read More →

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts

STRO-001 Targets CD74, Eradicates B-Cell Hematologic Malignancy & Prolongs Survival A Powerful Attack on Multiple Myeloma & Lymphoma   SOUTH SAN FRANCISCO, July 17, 2017.. Read More →

Sutro Appoints Lobacki as Director; Leonard, Krishnan & Levy as Advisors

SOUTH SAN FRANCISCO, April 27, 2017 –Sutro Biopharma Inc. is adding an expert in drug commercialization to its board of directors, appointing clinical and scientific.. Read More →

Sutro ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival in Tumor Models

SOUTH SAN FRANCISCO, April 3, 2017 – STRO-001, an antibody drug conjugate developed by Sutro Biopharma Inc., demonstrated potent anti-tumor activity in multiple myeloma, diffuse.. Read More →

Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant Cell Lines and Animal Models of Non-Hodgkin Lymphoma and Multiple Myeloma

SOUTH SAN FRANCISCO, December 6, 2016 – Sutro Biopharma Inc. today announced that it has launched IND-enabling studies, including preparation for GLP toxicology, of STRO-001,.. Read More →

Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma

SAN FRANCISCO, Sept. 19, 2016 — Sutro Biopharma Inc. today announced that it has presented findings from two studies of investigational antibody drug conjugates, or ADCs, that it.. Read More →

Sutro Marks Important Progress — Receives Two Milestone Payments from Celgene

SAN FRANCISCO, Sept. 7, 2016 – Sutro Biopharma Inc. today announced that it has received two milestone payments from drug discovery and development partner Celgene Corporation (Celgene).. Read More →

Sutro Appoints Shabbir T. Anik Chief Technical Operations Officer

SOUTH SAN FRANCISCO, June 1, 2016 – Sutro Biopharma today announced the appointment of Dr. Shabbir T. Anik to the newly-created position of chief technical.. Read More →

Sutro Expands Senior Leadership Team with Addition of Chief Medical Officer and VP of Translational Pharmacology and Preclinical Development

SOUTH SAN FRANCISCO, Mar. 9, 2016 – Sutro Biopharma today announced the appointment of Arturo Molina, M.D., M.S., FACP as chief medical officer and Mark.. Read More →

Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management

SAN FRANCISCO, Aug. 4, 2015 – Sutro Biopharma today announced that it has appointed Nicki Vasquez, Ph.D., as vice president of alliance and project management... Read More →

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

Deal expands Immuno-Oncology Product Discovery and Development Program and Aims to Accelerate Development of Oncology Therapeutics with Compelling Patient Benefit   SOUTH SAN FRANCISCO, Oct.. Read More →

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates

Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, to enhance its access to antibody drug conjugate technologies and to expand.. Read More →

Sutro Biopharma to Collaborate with University of California, San Francisco (UCSF), a Recombinant Antibody Network (RAN) Member

Collaboration to Express Antibodies and Antigens based on Sutro’s Technology Platform XpressCF+™ SAN FRANCISCO, Sept. 9, 2014 – Sutro Biopharma, a biopharmaceutical company developing a.. Read More →

Sutro Biopharma to Present at 21st Annual Future Leaders in the Biotech Industry Conference

SAN FRANCISCO, Mar. 24, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies,.. Read More →

Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma

SAN FRANCISCO, Jan. 07, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies,.. Read More →

Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products

SAN FRANCISCO, Dec. 11, 2013 – Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will.. Read More →

Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer

SAN FRANCISCO, Jan. 31, 2013 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro’s cell-free protein synthesis technology, today announced.. Read More →

Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates

SAN FRANCISCO, Jan. 3, 2013 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro’s cell-free protein synthesis technology, today announced.. Read More →

Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies

SAN FRANCISCO, Dec. 18, 2012 – Sutro Biopharma today announced a collaboration with Celgene Corporation to design and develop novel antibody drug conjugates (ADCs) and bispecific.. Read More →

Sutro Biopharma Expands Senior Management Team Jeremy Bender, Ph.D., Joins as Chief Business Officer; Aaron K. Sato, Ph.D., Named Vice President, Research

SAN FRANCISCO, October 24, 2012 – Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted.. Read More →

Sutro Closes $16.5 Million Second Tranche of Series C Financing

SAN FRANCISCO, May 8, 2012 – Sutro Biopharma today announced the closing of the $16.5 million second tranche of its Series C financing. This financing was.. Read More →

Sutro Announces Newly Formed Scientific Advisory Board Renowned Researchers James A. Wells, Ph.D., and James R. Swartz, Sc.D., to Guide Sutro’s Advancing Therapeutic Pipeline

SAN FRANCISCO, Jan. 7, 2012 – Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has.. Read More →

Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin

SAN FRANCISCO, Oct. 17, 2011 – Sutro’s Chief Scientific Officer, Trevor Hallam, Ph.D., to Highlight Company’s Technology Platform for the Highly Specific Design and Manufacturing of.. Read More →

Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics. Company’s First Major Collaboration Validates Potential of Biochemical Protein Synthesis Technology Platform.

San Francisco, CA Jan. 7, 2011 – Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the.. Read More →

Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer Appointment Reflects Biopharmaceutical Company’s Commitment to the Development of Novel and Biosuperior Protein Therapeutics

San Francisco, CA Dec. 8, 2010 – Sutro Biopharma, a biopharmaceutical company developing both novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that.. Read More →

Sutro Biopharma Secures $36.5 Million in Series C Financing

South San Francisco, CA Nov. 17, 2010 – Sutro Biopharma today announced that the company has secured $36.5 million in Series C financing. This financing will.. Read More →

Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team

South San Francisco, CA (August 20, 2009) Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, today announced.. Read More →

Sutro Biopharma Adds to Extensive IP Portfolio with Two Newly Issued Patents and Two Patent Grant Notices — Covers the Only Cell-Free Synthesis Platform Applicable to Protein Discovery Through Production —

South San Francisco, CA (June 9, 2009) Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, announced today.. Read More →

Sutro Biopharma Hits Major Technical Milestone, Reaching 100 Liter Scale for the Company’s Open Cell-free Protein Synthesis Technology – Milestone Triggers $15 Million Series B Financing

South San Francisco, CA (March 30, 2009) Sutro Biopharma, Inc., a pioneer in open cell-free synthesis for the discovery and production of proteins, announced today the.. Read More →

William J. Newell Named Chief Executive Officer of Sutro Biopharma – Former CEO Daniel S. Gold, Ph.D. Becomes President and Chief Operating Officer – Company Notes Name Change from Fundamental Applied Biology and Relocation to South San Francisco

South San Francisco, CA (January 12, 2009) Sutro Biopharma, Inc., formerly known as Fundamental Applied Biology, today announced the appointment of William J. Newell as.. Read More →